title: Chemoprevention: First line of defence.
authors: Lauren
authors: L
authors: Gravitz
mesh_terms: D000818:Animals; D001241:Aspirin / Q000009:adverse effects / Q000494:pharmacology; D000068579:Celecoxib; D017322:Clinical Trials, Phase II as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000494:pharmacology; D004195:Disease Models, Animal; D018450:Disease Progression; D005260:Female; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D019833:Genistein / Q000494:pharmacology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000517:prevention & control; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000096:biosynthesis / Q000378:metabolism; D051379:Mice; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000517:prevention & control; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology* / Q000517:prevention & control*; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000517:prevention & control; D011073:Polyamines / Q000378:metabolism; D011230:Precancerous Conditions / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000473:pathology; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology; D018570:Risk Assessment; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology
chemical_list: D016861:Cyclooxygenase Inhibitors; D011073:Polyamines; D011720:Pyrazoles; D013449:Sulfonamides; D019833:Genistein; D051416:Focal Adhesion Protein-Tyrosine Kinases; D020778:Matrix Metalloproteinase 2; D000068579:Celecoxib; D001241:Aspirin